PMZ 2123

Drug Profile

PMZ 2123

Alternative Names: BQ 123

Latest Information Update: 01 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Midwestern University
  • Developer Banyu; Pharmazz; University of Glasgow; Western Infirmary
  • Class Cyclic peptides
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diabetic ketoacidosis
  • Preclinical Pain
  • Discontinued Arrhythmias; Cerebral ischaemia; Diabetic complications; Heart failure; Hypertension; Hypertension in pregnancy; Myocardial ischaemia; Peripheral vascular disorders; Stress ulcer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Oct 2017 Pharmazz in-licenses a patent from Midwestern University for Pain (for reversal of opioid tolerence)
  • 18 Oct 2017 Preclinical trials in Pain in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top